| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5704010 | Experimental Eye Research | 2017 | 8 Pages |
Abstract
The system of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated nuclease (Cas)9 is an effective instrument for revising the genome with great accuracy. This system has been widely employed to generate mutants in genomes from plants to human cells. Rapid improvements in Cas9 specificity in eukaryotic cells have opened great potential for the use of this technology as a therapeutic. Herein, we summarize the recent advancements of CRISPR-Cas9 use in research on human cells and animal models, and outline a basic and clinical pipeline for CRISPR-Cas9-based treatments of genetic eye diseases.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology and Microbiology (General)
Authors
Wenyi Wu, Luosheng Tang, Patricia A. D'Amore, Hetian Lei,